Document is current

Article History

Received: 4 December 2024

Accepted: 15 April 2025

First Online: 13 May 2025

Declarations

:

: hPSC cell lines (hESC and HEF-iPSC) were all donated by Professor Xiafei Fu. The hESC (WA01/WA09) were commercially purchased from WiCell Research Institute, USA. Besides, the HEF-iPSC were derived from WI-38 human embryonic fibroblast (ATCC, USA). All cell lines were obtained with documented ethical compliance, including institutional ethics approval and donor informed consent. UC-MSC used in this study were obtained from healthy donors with prior informed consent and approved by the Medical Ethics Committee of Zhujiang Hospital affiliated with Southern Medical University (Title: Assessment of the efficacy and mechanisms of MSC from different developmental origins in POI treatment; Approval Number: 2023-KY-125-01; Date of approval: 21/07/2023). Animal studies were conducted in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All procedures were approved by the Committee on the Ethics of Animal Experiments of Zhujiang Hospital affiliated with Southern Medical University (Title: Assessment of the efficacy and mechanisms of MSC from different developmental origins in POI treatment; Approval Number: LAEC-2022-170; Date of approval: 22/11/2022).

: All authors have approved the manuscript and agreed with its submission.

: The authors have no conflicts of interest.